Abstract:ID 92395 Poster Board 511 Opioid Use Disorder (OUD) is a chronic, relapsing disease that, despite our best research efforts, has become a worsening public health crisis. Currently, the medications to treat OUD belong to the opioid class of drugs and, therefore, continue to interact directly with opioid receptors. While these medications are safe and effective for the cessation of opioids with higher abuse potentials, there is still a need for effective non-opioid receptor-targeting therapeutics. Exploring novel non-opioid targets is necessary to overcome this barrier. One such non-opioid target we are currently investigating is the calcitonin gene-related peptide (CGRP) system, particularly CGRP-expressing neurons in the parabrachial nucleus (CGRP PBN ). These neurons have been well studied in itch and pain and are known to project to brain regions implicated in opioid reward and withdrawal. Previous studies in our lab have found that CGRP PBN activity decreases during opioid taking and increases during opioid withdrawal. To further characterize the behavioral role of CGRP PBN neurons in opioid withdrawal, Calca-Cre transgenic mice received viral injections into the PBN containing an inhibitory DREADD (hm4Di), and two weeks later, mice were implanted with 2x25 mg morphine pellets. After five days, morphine withdrawal was induced by removing the pellets. Mice were administered either clozapine-N-oxide (CNO) (3 mg/kg, I.P.) or vehicle (saline, I.P.) 5.5 hours post pellet removal, and behavior was recorded at 6 and 24 hours post pellet removal. Two experimenters scored videos for jumping and wet dog shakes. Those mice injected with CNO showed fewer wet-dog shakes at the 6-hour time than vehicle-injected controls. We next sought to characterize the behavioral role of CGRP PBN neurons in opioid taking. In this experiment, morphine intravenous self-administration (IVSA) was used. Calca-Cre transgenic mice received viral injections into the PBN containing either an inhibitory DREADD (hm4Di) or a control mCherry vector and, two weeks later, were implanted with jugular catheters. Subsequently, operant responding for intravenous morphine was established. After 12 daily sessions, mice were administered CNO (3 mg/kg, I.P.) or vehicle (saline, I.P.) and allowed to respond for morphine. CGRP PBN inhibition reduced morphine intake in hm4Di-injected animals, while those with a control virus maintained their previous levels of morphine intake. Decreases in morphine intake were maintained 24 hours after CNO administration but returned to previous baseline levels at 48 hours. These results suggest that CGRP PBN neurons play a role in the behavioral consequences of both opioid reinforcement and withdrawal. CGRP receptor inhibitors are FDA-approved for the treatment of migraine and exist in both short and long-lasting formulations. By leveraging these available medications for the off-label purpose of treating OUD, we may be able to determine the translational potential of these preclinical findings and, therefore, expand our therapeutic arsenal for long-term maintenance of opioid abstinence and relapse.

Differential Roles of Corticotropin‐releasing Factor Receptor Subtypes 1 and 2 in Opiate Withdrawal and in Relapse to Opiate Dependence

Corticotrophin-releasing hormone neurons in the central amygdala mediate morphine withdrawal-induced negative emotions

Blocking Alpha(4)Beta(2) And Alpha(7) Nicotinic Acetylcholine Receptors Inhibits The Reinstatement Of Morphine-Induced Cpp By Drug Priming In Mice

Ionotropic Glutamatergic Neurotransmission in the Ventral Tegmental Area Modulates ΔFosB Expression in the Nucleus Accumbens and Abstinence Syndrome in Morphine Withdrawal Rats

Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats

Region-specific effects of brain corticotropin-releasing factor receptor type 1 blockade on footshock-stress- or drug-priming-induced reinstatement of morphine conditioned place preference in rats

Effects of 5-HT1A Receptor Antagonist and 5-HT2A Receptor Agonist on Morphine Withdrawal

Distinctive roles of L-type calcium channels subtypes within the dorsal hippocampus in formation of morphine withdrawal-induced aversion in rats

Cholecystokinin-B Receptor Antagonists Attenuate Morphine Dependence and Withdrawal in Rats

Effectiveness Comparisons of G-protein Biased and Unbiased Mu Opioid Receptor Ligands in Warm Water Tail-Withdrawal and Drug Discrimination in Male and Female Rats

Mesoaccumbens Dopamine Signaling Alteration Underlies Behavioral Transition from Tolerance to Sensitization to Morphine Rewarding Properties During Morphine Withdrawal

Inhibition of Parabrachial CGRP Neurons Reduces Morphine Reinforcement and Withdrawal

Decreased Neuronal Excitability in Medial Prefrontal Cortex during Morphine Withdrawal is associated with enhanced SK channel activity and upregulation of small GTPase Rac1

Blockade of Cannabinoid CB1 Receptor Attenuates the Acquisition of Morphine-Induced Conditioned Place Preference along with a Downregulation of ERK, CREB Phosphorylation, and BDNF Expression in the Nucleus Accumbens and Hippocampus.

Effects of the altered activity of δ-opioid receptor on the expression of glutamate transporter type 3 induced by chronic exposure to morphine.

Activation of trace amine‐associated receptor 1 selectively attenuates the reinforcing effects of morphine

Acute and chronic morphine treatments and morphine withdrawal differentially regulate GRK2 and GRK5 gene expression in rat brain.

Clonidine Attenuates Morphine Withdrawal and Subsequent Drug Sensitization in Rhesus Monkeys

The differential effects of OX1R and OX2R selective antagonists on morphine conditioned place preference in naïve versus morphine-dependent mice

Downregulation of mGluR2/3 receptors during morphine withdrawal in rats impairs mGluR2/3- and NMDA receptor-dependent long-term depression in the nucleus accumbens.

Spinal kappa-opioid system plays an important role in suppressing morphine withdrawal syndrome in the rat